title: Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma.
abstract: Previous studies showed that celecoxib, a cyclooxygenase-2 (COX2) inhibitor, can inhibit angiogenesis and metastasis of pancreatic ductal adenocarcinoma (PDAC) via the suppression of specificity protein 1 (Sp1). In this study, we investigated the prognostic value of Sp1 and COX2 in 88 PDAC patients. Our study showed there was a positive correlation between Sp1 and COX2 expression (P=0.001) by using the Spearman's rank test. Pearson Chi-square test revealed that Sp1 and COX2 expression were positively associated with lymph node metastasis (P<0.05, both). In addition, the Kaplan-Meier analysis showed that patients with Sp1- or COX2-positive expression exhibited poorer overall survival (OS) than those with Sp1- or COX2-negative expression (P<0.05, all). Most importantly, Sp1- and COX2-negative patients had the best OS (P=0.01). In multivariate analysis, Sp1 expression (P=0.03), COX2 expression (P=0.04), and nuclear grade (P=0.009) were found to be independent predictors for OS. Moreover, we confirmed that Sp1 could upregulate the expression of COX2 in PDAC cell lines by western blot analysis, and both are of important prognostic value in PDAC.
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China.
authors.forename: Junjie
authors.initials: J
authors.lastname: Hang
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China.
authors.forename: Hai
authors.initials: H
authors.lastname: Hu
authors.affiliation: Department of Hematology, First Affiliated Hospital of Shenzhen University, Shenzhen 513000, China.
authors.forename: Junjie
authors.initials: J
authors.lastname: Huang
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Han
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China.
authors.forename: Meng
authors.initials: M
authors.lastname: Zhuo
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Anhui 233004, China.
authors.forename: Yangyang
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Radiation Oncology, Lianyungang First People's Hospital, Jiangsu 222002, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Jiao
authors.affiliation: Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.|Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China.
authors.forename: Liwei
authors.initials: L
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D021441:Carcinoma, Pancreatic Ductal / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D016329:Sp1 Transcription Factor / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D016329:Sp1 Transcription Factor; C108209:SP1 protein, human; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human
keywords: correlation; cyclooxygenase-2; pancreatic ductal adenocarcinoma; prognosis; specificity protein 1